Properties (62)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
Acquired_by_Biogen_in_2017_for_Spinraza
|
| gptkbp:advertising |
gptkb:Dr._David_A._Smith
|
| gptkbp:CEO |
gptkb:Brett_P._Monia
|
| gptkbp:clinicalTrials |
ongoing
multiple drugs Phase 3 for several drugs |
| gptkbp:collaborations |
with various pharmaceutical companies
Ionis_and_Biogen_for_nusinersen with_the_University_of_California,_San_Diego with_the_University_of_Cambridge with_the_University_of_Pennsylvania with_the_University_of_Toronto |
| gptkbp:employees |
approximately 500
|
| gptkbp:financialPerformance |
volatile
|
| gptkbp:focus |
RNA-targeted drug discovery
|
| gptkbp:focus_area |
cancer
eye diseases genetic disorders liver diseases neurodegenerative diseases autoimmune diseases chronic pain cardiovascular diseases infectious diseases skin diseases muscle diseases kidney diseases gastrointestinal diseases inflammatory diseases pulmonary diseases metabolic diseases endocrine diseases musculoskeletal diseases hematological diseases neuropsychiatric diseases |
| gptkbp:founded |
1989
|
| gptkbp:founder |
Stanley_T._Crooke
|
| gptkbp:headquarters |
gptkb:Carlsbad,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ionis Pharmaceuticals
|
| gptkbp:investmentFocus |
institutional and retail
|
| gptkbp:market |
approximately $4 billion (2023)
|
| gptkbp:notableFeature |
gptkb:Spinraza
Waylivra Tegsedi |
| gptkbp:partnerships |
gptkb:AstraZeneca
gptkb:Bristol-Myers_Squibb gptkb:Biogen gptkb:Bayer |
| gptkbp:patentCitation |
over 1,000
|
| gptkbp:patentType |
multiple drugs
|
| gptkbp:platforms |
Ionis'_proprietary_technology
|
| gptkbp:publications |
numerous
|
| gptkbp:research |
Dr._Frank_Bennett
|
| gptkbp:research_areas |
cardiology
neurology rare diseases |
| gptkbp:research_focus |
gptkb:antisense_oligonucleotides
|
| gptkbp:revenue |
$1.1 billion (2022)
|
| gptkbp:sells |
IONS
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:tributaryOf |
over 40 drugs in development
|